CD8A and neoplasm: Moreover, frOpn1 administration resulted in enhanced CD8+ T cell percentages into the tumor on day 4 after the onset of injections and also greater numbers of IFN-γ producers within the CD8+ T cell population compared with frOpn3, frOpn1 + DT, and frOpn3 + DT administration (Fig. 8 f).